Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025FLORHAM PARK, N.J. and LONDON…
Ritedose Lab Expansion Ritedose is growing in laboratory and drug development capacity - with the announcement of a $17M in-house…
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line…
Company honored in its commitment to patients and families living with mitochondrial disease; invites the community to walk with BPGbio…
Engagement Will Expand Daré’s Engagement in Advancing Women’s Health Innovation and Provide Insights into One of the Most Significant Unmet…
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is…
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million…
IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical…
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by…